Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Nov 2022)

Cardiac Resynchronization Therapy for Adult Patients With a Failing Systemic Right Ventricle: A Multicenter Study

  • Rohit K. Kharbanda,
  • Jeremy P. Moore,
  • Michael S. Lloyd,
  • Robert Galotti,
  • Ad J. J. C. Bogers,
  • Yannick J. H. J. Taverne,
  • Malini Madhavan,
  • Christopher J. McLeod,
  • Anne M. Dubin,
  • Douglas Y. Mah,
  • Philip M. Chang,
  • Anna N. Kamp,
  • Jens C. Nielsen,
  • Alper Aydin,
  • Ronn E. Tanel,
  • Maully J. Shah,
  • Thomas Pilcher,
  • Reinder Evertz,
  • Paul Khairy,
  • Reina B. Tan,
  • Richard J. Czosek,
  • Kalyanam Shivkumar,
  • Natasja M. S. de Groot

DOI
https://doi.org/10.1161/JAHA.121.025121
Journal volume & issue
Vol. 11, no. 22

Abstract

Read online

Background The objective of this international multicenter study was to investigate both early and late outcomes of cardiac resynchronization therapy (CRT) in patients with a systemic right ventricle (SRV) and to identify predictors for congestive heart failure readmissions and mortality. Methods and Results This retrospective international multicenter study included 13 centers. The study population comprised 80 adult patients with SRV (48.9% women) with a mean age of 45±14 (range, 18–77) years at initiation of CRT. Median follow‐up time was 4.1 (25th–75th percentile, 1.3–8.3) years. Underlying congenital heart disease consisted of congenitally corrected transposition of the great arteries and dextro‐transposition of the great arteries in 63 (78.8%) and 17 (21.3%) patients, respectively. CRT resulted in significant improvement in functional class (before CRT: III, 25th–75th percentile, II–III; after CRT: II, 25th–75th percentile, II–III; P=0.005) and QRS duration (before CRT: 176±27; after CRT: 150±24 milliseconds; P=0.003) in patients with pre‐CRT ventricular pacing who underwent an upgrade to a CRT device (n=49). These improvements persisted during long‐term follow‐up with a marginal but significant increase in SRV function (before CRT; 30%, 25th–75th percentile, 25–35; after CRT: 31%, 25th–75th percentile, 21–38; P=0.049). In contrast, no beneficial change in the above‐mentioned variables was observed in patients who underwent de novo CRT (n=31). A quarter of all patients were readmitted for heart failure during follow‐up, and mortality at latest follow‐up was 21.3%. Conclusions This international experience with CRT in patients with an SRV demonstrated that CRT in selected patients with SRV dysfunction and pacing‐induced dyssynchrony yielded consistent improvement in QRS duration and New York Heart Association functional status, with a marginal increase in SRV function.

Keywords